Carol Knott

TL;DR: Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease.

TL;DR: The EMPA-KIDNEY trial is an international randomized, double-blind, placebo-controlled trial assessing whether empagliflozin 10 mg daily decreases the risk of kidney disease progression or cardiovascular death in people with CKD.

TL;DR: UK HARP-III was a multicentre, double-blind, randomized controlled trial comparing the effects of sacubitril/valsartan and irbesartan on measured GFR after 12 months of therapy and important secondary outcomes include effects on albuminuria, change in eGFR over time and the safety and tolerability of sacubsubitrin/valsArtan in CKD.

TL;DR: O Oversight of this trial was augmented by central statistical monitoring that identified high scoring sites as priority for further investigation and some low scoring sites identified by the country teams as potentially problematic were visited.

TL;DR: A large number of respondents had been involved in both the recruitment and follow-up phases of HPS2-THRIVE, and the survey was easy to manage, with a relatively high response rate.